1. Sodium oligomannate disrupts the adherence of Ribhigh bacteria to gut epithelia to block SAA-triggered Th1 inflammation in 5XFAD transgenic mice
- Author
-
Xinyi Wang, Zuoquan Xie, Jie Yuan, Enjing Jin, Wen Lian, Shuaishuai Chang, Guangqiang Sun, Zhengnan Feng, Hui Xu, Chen Du, Xinying Yang, Aihua Xia, Ji Qiu, Qingli Zhang, Feifei Lin, Jia Liu, Liang Li, Xiaoguang Du, Zhongping Xiao, Zhou Yi, Zhiyu Luo, Changrong Ge, Rui Li, Mingyue Zheng, Yi Jiang, Tao Wang, Jing Zhang, Qihao Guo, and Meiyu Geng
- Subjects
Cytology ,QH573-671 - Abstract
Abstract Sodium oligomannate (GV-971), an oligosaccharide drug approved in China for treating mild-to-moderate Alzheimer’s disease (AD), was previously found to recondition the gut microbiota and limit altered peripheral Th1 immunity in AD transgenic mice. As a follow-up study, we here made advances by pinpointing a Lactobacillus murinus (L.m.) strain that highly expressed a gene encoding a putative adhesin containing Rib repeats (Ribhigh-L.m.) particularly enriched in 5XFAD transgenic mice. Mechanistically, Ribhigh-L.m. adherence to the gut epithelia upregulated fecal metabolites, among which lactate ranked as the top candidate. Excess lactate stimulated the epithelial production of serum amyloid A (SAA) in the gut via the GPR81-NFκB axis, contributing to peripheral Th1 activation. Moreover, GV-971 disrupted the adherence of Ribhigh-L.m. to gut epithelia via direct binding to Rib, which corrected the excess lactate, reduced SAA, and alleviated Th1-skewed inflammation. Together, we gained further insights into the molecular link between gut bacteria and AD progression and the mechanism of GV-971 in treating AD.
- Published
- 2024
- Full Text
- View/download PDF